跳至主要内容
临床试验/NCT04371913
NCT04371913招募中不适用

Personalized Second Chance Breast Conservation (PSCBC): A Two Center Prospective Phase II Clinical Study

Weill Medical College of Cornell University3 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2020年6月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
120
试验地点
3
主要终点
Rate of treatment related adverse events as graded by CTCAE version 5.0

研究概览

简要总结

The goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with in-breast recurrences after a previous lumpectomy and RT, investigators propose to test partial breast irradiation with the target volume encompassing the entire surgical bed with 1.0-1.5 cm margins.

An additional goal of the study is to investigate the feasibility of enabling a second chance for breast conservation in patients with inbreast recurrences after a previous lumpectomy and PBI, the investigators propose to test whole breast RT (WBRT) with the target as the whole breast volume.

详细描述

Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated fractionation scheme of choice for Radiation Therapy (RT) naïve patients at New York Presbyterian using EBRT or with the fractionation of 4050 cGy in 15 fractions over 3 weeks, based on the previous treatment that they received.

The main aim of the study is to evaluate the rate of early grade 3 toxicities with this approach.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 90 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Isolated ipsilateral unifocal breast lesions
  • Limited size (< 2-3 cm) without evidence of skin involvement
  • Histologically proven invasive breast carcinoma or carcinoma in situ
  • Negative histologic margins of resection
  • Patients with 0 to 3 positive axillary lymph nodes without extracapsular extension
  • No synchronous distant metastases
  • Age ≥ 18 years
  • ≥ 12 months interval between initial breast conserving therapy (surgery and whole breast radiotherapy) and recurrence
  • Previous WBI or IORT, brachytherapy or external beam partial breast treatment
  • Technical feasibility
  • Every kind of systemic therapy is allowed
  • Informed consent for clinical and research purposes signed

排除标准

  • Regional recurrences (axillary, supraclavicular)
  • Positive histologic margins at resection
  • Metastatic disease
  • Poor cosmesis from previous surgery and RT
  • Extensive Intraductal Component

研究组 & 干预措施

Radiation Therapy - PBI

Other

Patients will be treated with the fractionation of 30 Gy in 5 fractions over 1-2 weeks, which is the accelerated partial breast irradiation (PBI) fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT)

干预措施: 600cGY x 5 fractions APBI (Radiation)

Radiation Therapy - WBRT

Other

Patients will be treated with the fractionation of 4050 cGy in 15 fractions over 3 weeks, which is the standard whole breast RT (WBRT) fractionation scheme of choice for RT naïve patients at New York Presbyterian using External Beam Radiation Therapy (EBRT)

干预措施: 270cGy x 15 fractions WBRT (Radiation)

结局指标

主要结局

Rate of treatment related adverse events as graded by CTCAE version 5.0

时间窗: up to 1 year from completion of radiation treatment

The primary endpoint of the study is to test the feasibility in terms of acute toxicity of a protocol of partial breast re-irradiation for breast cancer treatment in a previously irradiated whole breast, as defined by the rate of grade ≥ 3 treatment-related skin, fibrosis, and breast pain AEs, as graded by CTCAE version 5.0.

次要结局

  • Disease free survival (DFS) will be measured(60 months)
  • Number of participants with late toxicity will be measured as graded by CTCAE version 5.0(up to 60 months)
  • Overall Survival (OS) will be measured.(60 months)
  • Number of participants who received subsequent mastectomy in the treated breast(60 months)
  • Change in number of participants with skin changes(baseline, approx. week 1- week 2 of radiation, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months.)
  • Number of participants who demonstrate local control(60 months)
  • Change in Quality of life as assessed by Breast Cancer treatment outcome scale (BCTOS)(baseline, approx. week 1- week 2 of radiation, 6 months, 12 months, 24 months, 36 months, 48 months, 60 months.)
  • Number of participants who received subsequent mastectomy in the treated breast(6 months)
  • Number of participants who received subsequent mastectomy in the treated breast(12 months)
  • Number of participants who received subsequent mastectomy in the treated breast(24 months)
  • Number of participants who received subsequent mastectomy in the treated breast(36 months)
  • Number of participants who received subsequent mastectomy in the treated breast(48 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验